DNLI

Equity

Denali Therapeutics Inc.

Health Care · Biotechnology

$21.18

+21.18 (+0.00%)

Open

N/A

Day Range

$20.25 - $21.45

52W Range

$10.57 - $23.77

Volume

1M

Price History

Key Statistics

Market Cap

N/A

P/E Ratio

N/A

EPS

N/A

Dividend Yield

N/A

P/B Ratio

N/A

Payout Ratio

N/A

ROE

N/A

Debt/Equity

N/A

Latest News

Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

GlobeNewswire 1 day ago

Denali Therapeutics Showcases ETV Data at WORLD: TIVI PDUFA Near, DNL126 Hits 80% CSF Drop

MarketBeat Feb 5, 2026

Denali Therapeutics Presents Enzyme TransportVehicle™ Progress Across Three Clinical Programs for Treatment of Lysosomal Storage Disorders at 2026 WORLDSymposium™

GlobeNewswire Feb 5, 2026

A Look At Denali Therapeutics (DNLI) Valuation As New ETV Rare Disease Data Presentations Approach

Simply Wall St. Feb 5, 2026

How Denali’s Brain-Targeted ETV Data and FDA Review Will Impact Denali Therapeutics (DNLI) Investors

Simply Wall St. Feb 4, 2026

Peers in Health Care

Symbol Name Price Mkt Cap Div Yield Change
ABCL AbCellera Biologics Inc. $3.61 N/A - +0.00%
ABUS Arbutus Biopharma Corporation $4.66 N/A - +0.00%
001540.KQ AHN-GOOK PHA $8,070.00 N/A 5.45% +0.00%
AKBA Akebia Therapeutics, Inc. $1.31 N/A - +0.00%
AHCO AdaptHealth Corp. $9.15 N/A - +0.00%
ABBV AbbVie Inc. $232.08 N/A 2.87% +0.00%
ACAD ACADIA Pharmaceuticals Inc. $24.56 N/A - +0.00%
CRSP CRISPR Therapeutics AG $60.14 N/A - +0.00%

Community Sentiment

Sign in to vote

0% Bullish 0% Neutral 100% Bearish

0 votes

Discussion (0)

Sign in to join the discussion

Loading comments...

About Denali Therapeutics Inc.

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; DNL343 eIF2B activator program for amyotrophic lateral sclerosis; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

www.denalitherapeutics.com →

Dividend Safety

Assessment based on payout ratio, debt levels, profit margins, and dividend growth track record.

50

Borderline

Based on 4 fundamental factors

Analysis Tools

Sign in for analysis tools

Share